Abstract
The activated clotting time (ACT) with a Hemochron system for determining heparin requirements during cardiopulmonary bypass surgery, (CPB) accompanied by hemodilution and hypothermia was evaluated using plasma heparin levels as a standard. In 28 patients who were administered a standard heparin regimen (300 units/kg prebypass, 8000 units in the pump prime and 100 units/kg hourly during CPB) mean prebypass plasma heparin was 4 units/ml, and ACT was 493 seconds. During CPB mean plasma heparin decreased significantly (p < 0.001) to 3.1 units/ml, whereas mean ACT increased significantly (p < 0.001) to 674 seconds. The mean protamine requirement predicted from ACT was significantly higher (43%) than predicted from plasma heparin levels or actual protamine administered. The ACT neither accurately reflected plasma heparin during CPB nor predicted protamine requirements. The fixed-dose regimen employed, however, prevented both intraoperative thrombosis, assessed clinically in all patients, and clotting on six arterial line filters, as determined by scanning EM, despite wide variations in ACT and plasma heparin levels during surgery.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arkin C. F., Shahsavari M., Copeland B. E., Kim A. Evaluation of the activated clotting time to control heparin andprotamine dosage in open-heart surgery. J Thorac Cardiovasc Surg. 1978 May;75(5):790–792. [PubMed] [Google Scholar]
- Bull B. S., Huse W. M., Brauer F. S., Korpman R. A. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975 May;69(5):685–689. [PubMed] [Google Scholar]
- Bull B. S., Korpman R. A., Huse W. M., Briggs B. D. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975 May;69(5):674–684. [PubMed] [Google Scholar]
- Hattersley P. G. Activated coagulation time of whole blood. JAMA. 1966 May 2;196(5):436–440. [PubMed] [Google Scholar]
- Hattersley P. G. Progress report: the activated coagulation time of whole blood (ACT). Am J Clin Pathol. 1976 Nov;66(5):899–904. doi: 10.1093/ajcp/66.5.899. [DOI] [PubMed] [Google Scholar]
- Hawksley M. De-heparinisation of blood after cardiopulmonary bypass. Lancet. 1966 Mar 12;1(7437):563–565. doi: 10.1016/s0140-6736(66)90759-8. [DOI] [PubMed] [Google Scholar]
- Sato T., Shamoto M. A simple rapid polychrome stain for epoxy-embedded tissue. Stain Technol. 1973 Sep;48(5):223–227. doi: 10.3109/10520297309116628. [DOI] [PubMed] [Google Scholar]
- Schriever H. G., Epstein S. E., Mintz M. D. Statistical correlation and heparin sensitivity of activated partial thromboplastin time, whole blood coagulation time, and an automated coagulation time. Am J Clin Pathol. 1973 Sep;60(3):323–329. doi: 10.1093/ajcp/60.3.323. [DOI] [PubMed] [Google Scholar]
- Stenbjerg S., Berg E., Albrechtsen O. K. Evaluation of the activated whole blood clotting time (ACT) in vitro. Scand J Haematol. 1979 Sep;23(3):239–244. doi: 10.1111/j.1600-0609.1979.tb02698.x. [DOI] [PubMed] [Google Scholar]
- Wessler S., Gitel S. N. Heparin: new concepts relevant to clinical use. Blood. 1979 Apr;53(4):525–544. [PubMed] [Google Scholar]
- Yin E. T., Wessler S., Butler J. V. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med. 1973 Feb;81(2):298–310. [PubMed] [Google Scholar]